Intravascular ultrasound (IVUS)-guided PCI was associated with lower long-term risk of cardiac death than an angiography-guided approach in patients with complex lesions, according to a single-center study published in JACC: Cardiovascular Interventions.
A remote monitoring protocol for heart failure patients with implantable electronic devices helped more of them stay out of the hospital over a one-year period than standard in-person visits, researchers reported at EHRA 2019.
Richard Kovacs, MD, left, assumes the role of American College of Cardiology president from C. Michael Valentine, MD, on March 18 at the ACC's scientific sessions in New Orleans (Photo by Todd Buchanan/ACC).
Richard Kovacs, MD, officially began his one-year stint as the president of the American College of Cardiology on March 18. The occasion was marked during a convocation ceremony on the final day of the ACC’s scientific sessions in New Orleans.
NEW ORLEANS — A new analysis considering not only a patient's first cardiovascular event—but the second, third and beyond—paints the REDUCE-IT trial in an even more positive light.
NEW ORLEANS — An antithrombotic regimen of apixaban plus a P2Y12 inhibitor such as clopidogrel lowered bleeding events and hospitalizations compared to warfarin plus clopidogrel in a cohort of patients with atrial fibrillation (AFib) and a recent acute coronary syndrome (ACS), according to results of the AUGUSTUS trial.
NEW ORLEANS — Patients who received the MitraClip device to treat heart failure with secondary mitral regurgitation showed significant and lasting improvements on a quality-of-life assessment compared to people treated with optimal medical therapy alone, according to a substudy of the COAPT trial presented at the American College of Cardiology’s scientific sessions.
NEW ORLEANS — Described by its authors as “a one-stop shop” for the primary prevention of cardiovascular disease, a new guideline released March 17 by the American Heart Association (AHA) and the American College of Cardiology (ACC) runs the gamut from smoking cessation strategies to specific recommendations for treating cholesterol based on a patient’s 10-year risk of atherosclerotic cardiovascular disease.
NEW ORLEANS — Two trials evaluating transcatheter aortic valve replacement (TAVR) in low-risk patients haven’t just shifted the TAVR versus surgical AVR discussion. They’ve completely flipped it, said experts here at the American College of Cardiology’s scientific sessions.
The FDA’s preliminary investigation into the long-term safety of paclitaxel-coated balloons and stents revealed those devices are associated with a 50 percent higher risk of death than control devices used to treat femoropopliteal artery disease.
Patients who received aortic valve repair or replacement (AVR) based on Class II indications fared better than those who underwent surgery for Class I triggers in a single-center study, suggesting earlier intervention may be warranted in asymptomatic individuals with chronic aortic regurgitation.
